Endo International plc – (ENDP) Expected to Post Quarterly Sales of $765.33 Million

Equities research analysts predict that Endo International plc – (NASDAQ:ENDP) (TSE:ENL) will announce sales of $765.33 million for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for Endo International’s earnings, with estimates ranging from $750.26 million to $779.46 million. Endo International reported sales of $1.24 billion in the same quarter last year, which would suggest a negative year-over-year growth rate of 38.3%. The company is scheduled to report its next earnings report before the market opens on Tuesday, February 27th.

According to Zacks, analysts expect that Endo International will report full-year sales of $765.33 million for the current fiscal year, with estimates ranging from $3.45 billion to $3.51 billion. For the next financial year, analysts expect that the company will post sales of $3.07 billion per share, with estimates ranging from $2.89 billion to $3.20 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Endo International.

A number of research analysts have issued reports on the stock. Cantor Fitzgerald reduced their price objective on shares of Endo International from $9.00 to $7.00 and set a “neutral” rating on the stock in a research report on Friday, November 10th. ValuEngine downgraded shares of Endo International from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. BidaskClub raised shares of Endo International from a “sell” rating to a “hold” rating in a research report on Tuesday, December 12th. BMO Capital Markets reduced their price objective on shares of Endo International from $11.00 to $10.00 and set a “market perform” rating on the stock in a research report on Friday, November 10th. Finally, Guggenheim assumed coverage on shares of Endo International in a research report on Tuesday, December 12th. They set a “neutral” rating and a $8.50 price objective on the stock. Three research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $10.54.

Endo International (ENDP) traded down $0.02 during trading hours on Wednesday, reaching $6.24. 8,828,230 shares of the company were exchanged, compared to its average volume of 5,471,246. The company has a quick ratio of 0.86, a current ratio of 1.08 and a debt-to-equity ratio of 10.78. The company has a market cap of $1,397.94, a price-to-earnings ratio of -0.28, a P/E/G ratio of 2.18 and a beta of 0.29. Endo International has a 52 week low of $5.77 and a 52 week high of $14.45.

Several large investors have recently added to or reduced their stakes in ENDP. Diamond Hill Capital Management Inc. boosted its stake in Endo International by 46.8% in the 3rd quarter. Diamond Hill Capital Management Inc. now owns 716,670 shares of the company’s stock worth $6,138,000 after purchasing an additional 228,426 shares in the last quarter. TIAA CREF Investment Management LLC boosted its stake in Endo International by 1.6% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 649,535 shares of the company’s stock worth $7,255,000 after purchasing an additional 10,387 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in Endo International by 4.9% in the 2nd quarter. Ameriprise Financial Inc. now owns 581,552 shares of the company’s stock worth $6,497,000 after purchasing an additional 27,414 shares in the last quarter. River & Mercantile Asset Management LLP boosted its stake in Endo International by 32.7% in the 4th quarter. River & Mercantile Asset Management LLP now owns 475,650 shares of the company’s stock worth $3,679,000 after purchasing an additional 117,110 shares in the last quarter. Finally, Parametric Portfolio Associates LLC boosted its stake in Endo International by 18.7% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 398,099 shares of the company’s stock worth $4,447,000 after purchasing an additional 62,822 shares in the last quarter. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Endo International plc – (ENDP) Expected to Post Quarterly Sales of $765.33 Million” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://sportsperspectives.com/2018/02/10/endo-international-plc-endp-expected-to-post-quarterly-sales-of-765-33-million.html.

About Endo International

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get a free copy of the Zacks research report on Endo International (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply